Integrin αVβ6: Autoantigen and Driver of Epithelial Remodeling in Colon and Bile Ducts in Primary Sclerosing Cholangitis and Inflammatory Bowel Disease - Scorecard - MDSpire
Advertisement
Integrin αVβ6: Autoantigen and Driver of Epithelial Remodeling in Colon and Bile Ducts in Primary Sclerosing Cholangitis and Inflammatory Bowel Disease
Clinical Scorecard: Integrin αVβ6: A Key Autoantigen and Contributor to Epithelial Changes in Primary Sclerosing Cholangitis and Inflammatory Bowel Disease
At a Glance
Category
Detail
Condition
Primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease (CD)
Key Mechanisms
Autoantibodies against epithelial adhesion protein integrin αVβ6 are associated with UC and PSC-IBD; integrin αVβ6 is expressed in disease-associated epithelia of bile duct and colon and may impair epithelial restitution by inhibiting fibronectin binding
Target Population
Patients with PSC with or without IBD, UC, CD, and other immune-mediated liver diseases
Care Setting
Tertiary care centers specializing in gastroenterology and hepatology
Key Highlights
Anti-integrin αVβ6 autoantibodies occur in 91% of UC, 73% of PSC-IBD, 39% of PSC without IBD, and are rare or absent in other liver diseases and healthy controls
Integrin αVβ6 is selectively expressed in epithelial cells of bile ducts and colon affected by disease
Anti-αVβ6 levels correlate moderately with intestinal disease activity in PSC-IBD but only weakly with biliary disease activity
Guideline-Based Recommendations
Diagnosis
Consider testing for anti-integrin αVβ6 IgG autoantibodies by ELISA in patients with suspected UC and PSC-IBD to support diagnosis
Use clinical, laboratory, endoscopic, and histological criteria alongside autoantibody testing for comprehensive assessment
Management
Monitor intestinal disease activity in PSC-IBD patients with anti-αVβ6 levels as a potential biomarker
Recognize that anti-αVβ6 autoantibodies may persist after proctocolectomy and may occur without clinically manifest IBD
Monitoring & Follow-up
Correlate anti-αVβ6 antibody levels with endoscopic disease activity during follow-up in PSC-IBD
Regular clinical and biochemical monitoring of biliary and intestinal disease activity remains essential
Risks
Anti-αVβ6 autoantibodies may contribute to impaired epithelial repair by inhibiting fibronectin binding, potentially exacerbating disease flares
Presence of anti-αVβ6 in PSC patients without IBD suggests subclinical epithelial alterations requiring careful evaluation
Patient & Prescribing Data
Patients with UC, PSC-IBD, PSC without IBD, and other immune-mediated liver diseases
Anti-αVβ6 autoantibody levels may serve as a biomarker for intestinal disease activity and could inform personalized management strategies; however, clinical utility requires further validation
Clinical Best Practices
Incorporate anti-integrin αVβ6 antibody testing in diagnostic workup for UC and PSC-IBD to improve disease characterization
Use anti-αVβ6 levels in conjunction with established clinical and endoscopic scores to monitor disease activity
Recognize the heterogeneity of PSC and PSC-IBD and tailor monitoring and treatment accordingly
Ensure ethical collection and storage of patient samples with informed consent and institutional approval
by Dominik Roth, Miriam M Düll, Ludwig J Horst, Aylin Lindemann, Xenia Malzer, Kristina Koop, Sebastian Zundler, Marcel Vetter, André Jefremow, Raja Atreya, Carol Geppert, Sören Weidemann, Maximilian J Waldner, Peter Dietrich, Claudia Günther, Luis E Munoz, Martin Herrmann, Alexander Scheffold, Markus F Neurath, Jürgen Siebler, Christoph Schramm, Andreas E Kremer, Moritz Leppkes
